EUCTR2020-002672-12-NL
Active, not recruiting
Phase 1
Frontotemporal dementia Imaging of Neuroinflammation, Degeneration and Microglia-Related Effects - FIND-MORE
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Frontotemporal dementia (FTD), including symptomatic patients and presymptomatic individuals with genetic mutations predisposing to FTD at a later stage in life.
- Sponsor
- Erasmus Medical Center
- Enrollment
- 32
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Able to tolerate the \[18F]DPA\-714 PET\-MRI scan procedures and to make an informed decision to participate in this study
- •\- Symptomatic patients must meet clinical criteria for FTD clinical syndromes
- •\- Presymptomatic individuals and healthy controls must show no objective evidence of cognitive impairment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 27
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 5
Exclusion Criteria
- •\- Has contraindications for MRI scanning, e.g. metal objects in the body, claustrophobia
- •\- Has evidence of structural brain abnormalities that are likely to interfere with the interpretation of PET scan
- •\- Has one or more comorbidities that may interfere with the outcomes of the study (e.g. significant immune disease, neurological disease, CNS malignancy)
- •\- Has a history of moderate or severe traumatic brain injury
- •\- Has made use of immunomodulatory or immunosuppressive therapy in the 3 months prior to the scan
- •\- Has any disease or uses medication that may compromise the function of the body systems and could interfere with the metabolism of the radiotracer or the interpretation of the results
- •\- Has an unstable medical condition
- •\- Is pregnant or breastfeeding
- •\- Has a history of severe drug allergy or hypersensitivity
- •\- Has been injected with a previously administered radiopharmaceutical within 6 terminal half\-lives OR when the total yearly radiation exposure exceeds 10 mSv if participating in this protocol
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Frontotemporal dementia Imaging of Neuroinflammation, Degeneration and Microglia-Related EffectsFrontotemporal dementiaFTD1004225810012272NL-OMON49263Erasmus MC, Universitair Medisch Centrum Rotterdam32
Terminated
Phase 1
PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) RadioligandDementiaNCT03958630National Institute of Mental Health (NIMH)13
Recruiting
Not Applicable
Advanced MR Neuroimaging in presenile dementianeurodegeneratieve aandoeningendementiaMRI10042258NL-OMON35133Erasmus MC, Universitair Medisch Centrum Rotterdam120
Active, not recruiting
Phase 1
IMAGING OF NEUROINFLAMMATION AND NEURODEGENERATION INALZHEIMER’S DISEASEmild cognitive impairment and familiar Alzheimer diseaseMedDRA version: 22.1Level: LLTClassification code 10050727Term: RI scanSystem Organ Class: 100000004848Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2015-001211-13-ITOSPEDALE SAN RAFFAELE38
Active, not recruiting
Not Applicable
study of neuroinflammation in pathologies like Alzheimer, mild cognitive impairment, dementia and SLAmild cognitive impairment, Alzheimer disease,frontotemporal dementia, SLAMedDRA version: 14.1Level: LLTClassification code 10050727Term: RI scanSystem Organ Class: 100000004848Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2012-004328-40-ITOSPEDALE S. RAFFAELE DI MILANO